Stock Track | Summit Therapeutics Soars on Bullish Analyst Coverage

Stock Track11-04

Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a "Market Outperform" rating.

JMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.

The positive analyst coverage acted as a catalyst for SMMT shares, which jumped as investors reacted to the optimistic outlook from JMP Securities. With the significant price target, the market appears to be anticipating further upside potential for Summit Therapeutics in the coming months.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106746439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106746439","market":"hk","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars on Bullish Analyst Coverage","media":"Stock Track","content":"<p>Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.</p>\n\n<p>JMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.</p>\n\n<p>The positive analyst coverage acted as a catalyst for SMMT shares, which jumped as investors reacted to the optimistic outlook from JMP Securities. With the significant price target, the market appears to be anticipating further upside potential for Summit Therapeutics in the coming months.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars on Bullish Analyst Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars on Bullish Analyst Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 23:46 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.\nJMP Securities analyst...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1106746439","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106746439","pubTimestamp":1730735192,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Summit Therapeutics PLC  soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.JMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.The positive analyst coverage acted as a catalyst for SMMT shares, which jumped as","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"分析师看涨报道导致Summit Therapeutics股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.\nJMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.\nThe positive analyst coverage acted as a catalyst for SMMT shares, which jumped as investors reacted to the optimistic outlook from JMP Securities. With the significant price target, the market appears to be anticipating further upside potential for Summit Therapeutics in the coming months.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106746439"}